Multicell's intellectual property portfolio is composed of several issued, pending or applied-for patents that cover its novel drug development platform technologies and new drug candidates. The Company is leveraging its breakthrough technology platforms to develop a new generation of therapeutic candidates which stimulate or suppress the immune system to treat such diseases as multiple sclerosis, type-1 diabetes and virus infections.